Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism—the EMIRA Study
- 18 February 2020
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (6) , 2060-2067
Abstract
Context: While current guidelines recommend the withdrawal of mineralocorticoid receptor antagonist (MRA) and renin-angiotensin system blockers for the screening and detection of primary aldosteronism (PA), this can worsen hypokalemia and control of high blood pressure (BP) values. Objective: To investigate whether aldosterone/renin ratio (ARR) values were affected by the MRA canrenone and/or by canrenone plus olmesartan treatment in patients with PA. Design: Within-patient study. Setting: The European Society of Hypertension center of excellence at the University of Padua. Patients: Consecutive patients with an unambiguous diagnosis of PA subtyped by adrenal vein sampling. Interventions: Patients were treated for 1 month with canrenone (50–100 mg orally), and for an additional month with canrenone plus olmesartan (10–20 mg orally). Canrenone and olmesartan were up-titrated over the first 2 weeks until BP values and hypokalemia were controlled. Patients with unilateral PA were adrenalectomized; those with bilateral PA were treated medically. Main Outcome Measures: BP, plasma levels of sodium and potassium, renin and aldosterone. Results: Canrenone neither lowered plasma aldosterone nor increased renin; thus, the high ARR and true positive rate remained unaffected. Addition of the angiotensin type 1 receptor blocker raised renin and slightly lowered aldosterone, which reduced the ARR and increased the false negative rate. Conclusions: At doses that effectively controlled serum potassium and BP values, canrenone did not preclude an accurate diagnosis in patients with PA. Addition of the angiotensin type 1 receptor blocker olmesartan slightly raised the false negative rate. Hence, MRA did not seem to endanger the accuracy of the diagnosis of PA.Keywords
Funding Information
- Italian Ministry of Health (RF2011-02352318)
- University of Padova (DOR1625891/16, DOR1670784/16, BIRD163255/16)
This publication has 29 references indexed in Scilit:
- Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertensionClinical Chemistry and Laboratory Medicine (CCLM), 2016
- The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2016
- Non-Steroidal Mineralocorticoid Receptor Antagonism for the Treatment of Cardiovascular and Renal DiseaseEuropean Journal of Heart Failure, 2015
- Adrenal Histopathology in Primary AldosteronismHypertension, 2015
- Outcome of Adrenal Vein Sampling Performed During Concurrent Mineralocorticoid Receptor Antagonist TherapyThe Journal of Clinical Endocrinology & Metabolism, 2014
- An Expert Consensus Statement on Use of Adrenal Vein Sampling for the Subtyping of Primary AldosteronismHypertension, 2014
- Primary aldosteronism: emerging trendsTrends in Endocrinology & Metabolism, 2013
- Effect of Atenolol on Aldosterone/Renin Ratio Calculated by Both Plasma Renin Activity and Direct Renin Concentration in Healthy Male VolunteersThe Journal of Clinical Endocrinology & Metabolism, 2010
- A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive PatientsJACC, 2006
- Toward Complete and Accurate Reporting of Studies of Diagnostic AccuracyAmerican Journal of Clinical Pathology, 2003